Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation

Schizophrenia Research

Volumn 118, Issue 1-3, 2010, Pages 189-200

  Schlagenhauf, Florian ^a   Dinges, Martin ^a   Beck, Anne ^a   Wüstenberg, Torsten ^a   Friedel, Eva ^a   Dembler, Theresa ^a   Sarkar, Rahul ^a   Wrase, Jana ^a   Gallinat, Jürgen ^a   Juckel, Georg ^b   Heinz, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antipsychotic agents; Aripiprazole; First generation antipsychotics; Frontal cortex; Functional magnetic resonance imaging; Schizophrenia; Working memory

Indexed keywords

ARIPIPRAZOLE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; PERAZINE;

ADULT; ARTICLE; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; PARIETAL LOBE; PRIORITY JOURNAL; REACTION TIME; SCHIZOPHRENIA; SEDATION; TASK PERFORMANCE; VISUAL CORTEX; VISUAL STIMULATION; WORKING MEMORY;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; CHLORPROMAZINE; FEMALE; GYRUS CINGULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PHOTIC STIMULATION; PIPERAZINES; QUINOLONES; REACTION TIME; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; VISUAL CORTEX; YOUNG ADULT;

EID: 77951978910     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.01.022     Document Type: Article

References (74)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van H.R., Gorman J.M., Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22:3708-3719.
2. Aleman A., Hijman R., de Haan E.H., Kahn R.S. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 1999, 156:1358-1366.
3. Barch D.M., Smith E. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol. Psychiatry 2008, 64:11-17.
4. Benes F.M. Emerging principles of altered neural circuitry in schizophrenia. Brain Res. Brain Res. Rev. 2000, 31:251-269.
5. Bertolino A., Caforio G., Blasi G., De C.M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 2004, 161:1798-1805.
6. Bush G., Luu P., Posner M.I. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn. Sci. 2000, 4:215-222.
7. Callicott J.H., Mattay V.S., Bertolino A., Finn K., Coppola R., Frank J.A., Goldberg T.E., Weinberger D.R. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb. Cortex 1999, 9:20-26.
8. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000, 10:1078-1092.
9. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol. Psychiatry 1999, 46:1388-1395.
10. Carter C.S., van Veen V. Anterior cingulate cortex and conflict detection: an update of theory and data. Cogn. Affect. Behav. Neurosci. 2007, 7:367-379.
11. Castner S.A., Williams G.V., Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000, 287:2020-2022.
12. Castner S.A., Goldman-Rakic P.S., Williams G.V. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl.) 2004, 174:111-125.
13. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., Bigelow L.B., Goldberg T.E., Berman K.F., Kleinman J.E. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 1991, 11:1907-1917.
14. Dixon A.L., Prior M., Morris P.M., Shah Y.B., Joseph M.H., Young A.M. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 2005, 48:236-245.
15. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995, 378:180-182.
16. Durstewitz D., Seamans J.K. The computational role of dopamine D1 receptors in working memory. Neural Netw. 2002, 15:561-572.
17. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Personality Disorders, (SCID-II) 1997, American Psychiatric Press, Inc., Washington, D.C.
18. First M.B., Spitzer R.L., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN) 2001, New York State Psychiatric Institute, New York.
19. Fleischhacker W.W. Aripiprazole. Expert Opin. Pharmacother. 2005, 62:2091-2101.
20. Forbes N.F., Carrick L.A., McIntosh A.M., Lawrie S.M. Working memory in schizophrenia: a meta-analysis. Psychol. Med. 2008, 1-17.
21. Friston K.J., Holmes A.P., Worsley K.J., Poline J.B., Frith C.D., Frackowiak R.S.J. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 1995, 2:189-210.
22. Fumagalli F., Frasca A., Racagni G., Riva M.A. Dynamic regulation of glutamatergic post-synaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol. Pharmacol. 2008, 73(5):1484-1490.
23. Gibbs S.E., D'Esposito M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl.) 2005, 180:644-653.
24. Glahn D.C., Ragland J.D., Abramoff A., Barrett J., Laird A.R., Bearden C.E., Velligan D.I. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain Mapp. 2005, 25:60-69.
25. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
26. Heinz A., Romero B., Gallinat J., Juckel G., Weinberger D.R. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry 2003, 36(Suppl 3):S152-S157.
27. Hoddes E., Zarcone V., Smythe H., Phillips R., Dement W.C. Quantification of sleepiness: a new approach. Psychophysiology 1973, 10:431-436.
28. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13432-13437.
29. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76:1521-1531.
30. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004, 483:45-53.
31. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
32. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
33. Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl.) 2006, 187:312-320.
34. Kessler R.M., Woodward N.D., Riccardi P., Li R., Ansari M.S., Anderson S., Dawant B., Zald D., Meltzer H.Y. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry 2009, 65:1024-1031.
35. Kotrla K.J., Weinberger D.R. Brain imaging in schizophrenia. Annu. Rev. Med. 1995, 46:113-122.
36. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., bi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatr. 1999, 7:125-143.
37. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., Tamminga C.A. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry 2003, 53:601-608.
38. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., Frey K.N., Hardin M., Tamminga C.A. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 2004, 29:171-178.
39. Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., Kochunov P.V., Nickerson D., Mikiten S.A., Fox P.T. Automated Talairach atlas labels for functional brain mapping. Hum. Brain Mapp. 2000, 10:120-131.
40. Lee J., Park S. Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. 2005, 114:599-611.
41. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004, 493:75-83.
42. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
43. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 2003, 19:1233-1239.
44. Manoach D.S., Gollub R.L., Benson E.S., Searl M.M., Goff D.C., Halpern E., Saper C.B., Rauch S.L. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol. Psychiatry 2000, 48:99-109.
45. Mattay V.S., Berman K.F., Ostrem J.L., Esposito G., Van Horn J.D., Bigelow L.B., Weinberger D.R. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J. Neurosci. 1996, 16:4816-4822.
46. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6186-6191.
47. Mehta M.A., Montgomery A.J., Kitamura Y., Grasby P.M. Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology (Berl.) 2008, 196:157-165.
48. Meisenzahl E.M., Scheuerecker J., Zipse M., Ufer S., Wiesmann M., Frodl T., Koutsouleris N., Zetzsche T., Schmitt G., Riedel M., Spellmann I., Dehning S., Linn J., Bruckmann H., Moller H.J. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:522-531.
49. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5:267-271.
50. Minzenberg M.J., Laird A.R., Thelen S., Carter C.S., Glahn D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 2009, 66:811-822.
51. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Desco M., Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl.) 2005, 178:17-26.
52. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
53. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
54. Owen A.M., McMillan K.M., Laird A.R., Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum. Brain Mapp. 2005, 25:46-59.
55. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., Ell P.J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 2006, 11:118-119.
56. Ranganath C., Minzenberg M.J., Ragland J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol. Psychiatry 2008, 64:18-25.
57. Rowley H.L., Needham P.L., Kilpatrick I.C., Heal D.J. A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 361:187-192.
58. Schlagenhauf F., Wustenberg T., Schmack K., Dinges M., Wrase J., Koslowski M., Kienast T., Bauer M., Gallinat J., Juckel G., Heinz A. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur. Neuropsychopharmacol. 2008, 18:589-599.
59. Schlosser R.G., Koch K., Wagner G., Nenadic I., Roebel M., Schachtzabel C., Axer M., Schultz C., Reichenbach J.R., Sauer H. Inefficient executive cognitive control in schizophrenia is preceded by altered functional activation during information encoding: an fMRI study. Neuropsychologia 2008, 46:336-347.
60. Schmidt K., Metzler P. Wortschatztest (WST) 1992, Beltz test, Weinheim.
61. Suhara T., Sudo Y., Okauchi T., Maeda J., Kawabe K., Suzuki K., Okubo Y., Nakashima Y., Ito H., Tanada S., Halldin C., Farde L. Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int. J. Neuropsychopharmacol. 1999, 2:73-82.
62. Suhara T., Okubo Y., Yasuno F., Sudo Y., Inoue M., Ichimiya T., Nakashima Y., Nakayama K., Tanada S., Suzuki K., Halldin C., Farde L. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 2002, 59:25-30.
63. Takahashi H., Higuchi M., Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol. Psychiatry 2006, 59:919-928.
64. Vijayraghavan S., Wang M., Birnbaum S.G., Williams G.V., Arnsten A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 2007, 10:376-384.
65. Weickert T.W., Goldberg T.E. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr. Psychiatry Rep. 2005, 7:304-310.
66. Weiss E.M., Bilder R.M., Fleischhacker W.W. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl.) 2002, 162:11-17.
67. Wickens T.D. Elementary signal detection theory 2002, Oxford University Press, Oxford; New York.
68. Williams G.V., Castner S.A. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006, 139:263-276.
69. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
70. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex 1998, 8:321-345.
71. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
72. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.
73. Woodward T.S., Cairo T.A., Ruff C.C., Takane Y., Hunter M.A., Ngan E.T. Functional connectivity reveals load dependent neural systems underlying encoding and maintenance in verbal working memory. Neuroscience 2006, 139:317-325.
74. Zocchi A., Fabbri D., Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 2005, 387:157-161.